Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00458861 · ClinicalTrials.gov registry record · Phase 2
BG9924 in Combination With Methotrexate for Participants With Active Rheumatoid Arthritis
A Phase 2 study, sponsored by Biogen.
- Terminated
- Registry status
- Phase 2
- Development phase
- 115
- Enrollment target
NCT00458861 is a Phase 2 study that was terminated before completion, run by Biogen. The registered enrollment target is 115 participants.
The verdict
NCT00458861, a Phase 2 study, was terminated before completion, sponsored by Biogen.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 115 participants
- Enrollment target
Study Summary
This Phase 2b study is designed to evaluate the efficacy and safety of BG9924 given subcutaneously (SC) versus placebo in participants with active rheumatoid arthritis (RA) who have previously had an inadequate response to treatment with anti-tumor necrosis factor (anti-TNF) therapy.
Interventions
- OTHER Placebo Comparator
- BIOLOGICAL BG9924
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2007-03 |
| Est. Completion | 2008-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00458861
The ClinicalTrials.gov registry entry for NCT00458861 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 115 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Comparator is the first listed.
NCT00458861 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00458861 about?
NCT00458861 is a clinical study titled "BG9924 in Combination With Methotrexate for Participants With Active Rheumatoid Arthritis". This Phase 2b study is designed to evaluate the efficacy and safety of BG9924 given subcutaneously (SC) versus placebo in participants with active rheumatoid arthritis (RA) who have previously had an inadequate response to treatment with anti-tumor necrosis factor (anti-TNF) therapy.
What is the current status of trial NCT00458861?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 115 participants. The study started on 2007-03. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00458861?
The interventions under investigation include: Placebo Comparator (OTHER), BG9924 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00458861?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.